Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies
✍ Scribed by Giovanni Scambia; Pierluigi Benedetti Panici; Stefano Iacobelli; Gabriela Baiocchi; Francesco Battaglia; Lidia Perrone; Carla Sonsini; Gabriella Ferrandina; Clara Natoli; Salvatore Mancuso
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 372 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
The circulating levels of a 90-kilodalton (K) tumor-associated antigen were measured in the blood of 43 patients with gynecologic and breast malignancies who underwent a short course of recombinant alpha-2b-interferon (rIFN a-zb) (3 million U/m2/d intramuscularly [IM] for 3 days). Of the 43 patients, 23 showed abnormal 90-K levels (> 1.7 U/ml). A significant increase of antigen levels was already observed 24 hours after the first administration and persisted throughout the investigation period. Of 20 patients with 90-K levels below the normal limit, 1 2 went over the normal cutoff value after two rIFN a-2b injections. No significant modifications of 90-K levels were detected in nine women receiving rIFN a-2b for the treatment of genital condylomata. The serum levels of two other tumorassociated antigens, CA 125 and CA 15-3, were not modified by rIFN a-2b administration. The ability of rIFN a-2b to increase the circulating levels of 90-K might have important clinical implications for the serodetection of cancer.